PASG
Passage Bio Inc.
Company Overview
| Mkt Cap | $33.06M | Price | $9.80 |
| Volume | 77.33K | Change | -8.29% |
| P/E Ratio | -0.5 | Open | $10.50 |
| Revenue | $1.0M | Prev Close | $10.68 |
| Net Income | $-64.8M | 52W Range | $5.12 - $20.20 |
| Div Yield | N/A | Target | $32.50 |
| Overall | 58 | Value | 60 |
| Quality | 34 | Technical | 80 |
No chart data available
About Passage Bio Inc.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PASG | $9.80 | -8.3% | 77.33K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |